NCT01003171

Brief Summary

This study is to examine the pharmacokinetics, absorption and serum concentrations of MCS and other components after once-daily oral dosing of MCS.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
12

participants targeted

Target at below P25 for phase_1 healthy

Timeline
Completed

Started Aug 2011

Longer than P75 for phase_1 healthy

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 26, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 28, 2009

Completed
1.8 years until next milestone

Study Start

First participant enrolled

August 1, 2011

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

June 30, 2011

Status Verified

June 1, 2011

Enrollment Period

1.3 years

First QC Date

October 26, 2009

Last Update Submit

June 28, 2011

Conditions

Keywords

PharmacokineticsPKMCSBenign Prostatic HyperplasiaMulti-CarotenoidsHealthy subjects

Outcome Measures

Primary Outcomes (1)

  • Serum MCS and other components levels

    21 days

Secondary Outcomes (1)

  • Incidence of treatment-emergent adverse events

    21 days

Study Arms (1)

MCS-2

EXPERIMENTAL
Drug: MCS-2 soft-gel capsule

Interventions

MCS-2 30 mg/day

Also known as: MUS
MCS-2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Normal healthy volunteers
  • years of age or older

You may not qualify if:

  • Subjects who can not comply with the study procedures or sign the informed consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Prostatic Hyperplasia

Condition Hierarchy (Ancestors)

Prostatic DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 26, 2009

First Posted

October 28, 2009

Study Start

August 1, 2011

Primary Completion

December 1, 2012

Study Completion

December 1, 2012

Last Updated

June 30, 2011

Record last verified: 2011-06